피임약 시장 : 예측(2025-2030년)

The contraceptive market is expected to grow at a CAGR of 6.48%, reaching a market size of US$47.386 billion in 2030 from US$34.613 billion in 2025.

Contraception is the application that prevents a woman from pregnancy through medications or devices. Other commonly known as fertility control and birth control. The market is expected to continue growing as the incidence of STDs rises. More women are seeking contraceptive medicines and devices, particularly among young women who are beginning to use contraception as they attain higher levels of education.

Furthermore, the health risks posed by teenage pregnancy, increased awareness regarding modern contraceptive methods, and a growing preference for oral contraceptives as the principal method to avoid unintended pregnancy are expected to drive market growth over the next few years.

Contraceptive Market Drivers

• The growing need for population control is contributing to the contraceptive market growth

Government measures to control population growth in various countries have increased awareness of family planning and contraception among women in both rural and urban areas. Additionally, rising incidences of unintended pregnancies have led to increased utilization of oral contraceptives, especially in developed markets. Particularly in Asian countries, the population is expanding at an incredible rate, impacting the microeconomic balance. The public and private sectors are working together to control this growing population, which should benefit sex education and the use of contraceptives in the years to come. This is expected to drive the market revenue for oral contraceptives during the forecast period.

Contraceptive Market Geographical Outlook:

• North America is witnessing exponential growth during the forecast period.

The market growth in North America includes the inclination of young people toward sexual activities and the high awareness of reproductive health and contraception among them regarding the matters. Teenagers in the regions need contraceptives more due to the introduction and spread of cheap generic products and devices. The expansion of publicly funded family planning services and the rise in social organization efforts in the US to increase access to contraception. Most importantly, the two government-aided initiatives where insurance covers contraceptive methods- the Affordable Care Act and Title X- have made these products accessible and affordable.

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

The contraceptive market is segmented and analyzed as follows:

By Product

• Drugs
• Contraceptive Pills
• Injectable Contraceptives
• Topical Contraceptives
• Devices
• Condoms
• Intrauterine Devices (IUDs)
• Diaphragms
• Rings
• Others

By Distribution Channel

• Online
• Offline

By Age Group

• 15-24 years
• 25-34 years
• 35-44 years
• Above 44 years

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Italy
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Processes

3. EXECUTIVE SUMMARY

• 3.1. Key Findings
• 3.2. CXO Perspective

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis
• 4.5. Analyst View

5. CONTRACEPTIVE MARKET BY PRODUCT

• 5.1. Introduction
• 5.2. Drugs
  • 5.2.1. Contraceptive Pills
  • 5.2.2. Injectable Contraceptives
  • 5.2.3. Topical Contraceptives
  • 5.2.4. Devices
• 5.3. Condoms
  • 5.3.1. Intrauterine Devices (IUDs)
  • 5.3.2. Diaphragms
  • 5.3.3. Rings
  • 5.3.4. Others

6. CONTRACEPTIVE MARKET BY DISTRIBUTIIN CHANNEL

• 6.1. Introduction
• 6.2. Online
• 6.3. Offline

7. CONTRACEPTIVE MARKET BY AGE GROUP

• 7.1. Introduction
• 7.2. 15-24 years
• 7.3. 25-34 years
• 7.4. 35-44 years
• 7.5. Above 44 years

8. CONTRACEPTIVE MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Product
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Age Group
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Product
  • 8.3.2. By Distribution Channel
  • 8.3.3. By Age Group
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Product
  • 8.4.2. By Distribution Channel
  • 8.4.3. By Age Group
  • 8.4.4. By Country
    • 8.4.4.1. United Kingdom
    • 8.4.4.2. Germany
    • 8.4.4.3. France
    • 8.4.4.4. Italy
    • 8.4.4.5. Spain
    • 8.4.4.6. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Product
  • 8.5.2. By Distribution Channel
  • 8.5.3. By Age Group
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Product
  • 8.6.2. By Distribution Channel
  • 8.6.3. By Age Group
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. India
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Taiwan
    • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Allergan plc (AbbVie)
• 10.2. ANSELL LTD.
• 10.3. Bayer AG
• 10.4. CooperSurgical Inc.
• 10.5. Merck & Co., Inc.,
• 10.6. Church & Dwight Co., Inc.
• 10.7. Veru Inc.
• 10.8. Mayer Laboratories, Inc.
• 10.9. Pfizer Inc.
• 10.10. Teva Pharmaceutical Industries Ltd.
• 10.11. Reckitt Benckiser Group plc
• 10.12. Mankind Pharma
• 10.13. Karex Berhad
• 10.14. Montage Laboratory
• 10.15. Pregna International Ltd.